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ABSTRACT
Introduction: Lixisenatide is a novel GLP-1
receptor agonist for the treatment of type 2
diabetes mellitus (T2DM). Its efficacy and safety
have been assessed in a series of phase 3 studies
included in the GetGoal program. In these
studies, lixisenatide was found to be superior
to placebo in glycemic control. The aim of this
meta-analysis was to assess the safety and
efficacy of lixisenatide as an adjunct therapy
in Asian patients with T2DM in adequately
controlled with oral antidiabetic drugs (OADs).
Methods: We performed a meta-analysis from
five lixisenatide phase 3 studies. In each of these
multiethnic studies, patients with T2DM
inadequately controlled (glycated hemoglobin,
HbA1c C7%) with established OADs were
randomized to lixisenatide or placebo for
24 weeks, with a balanced distribution of Asian
patients in these two arms (503 and 338
patients in the intent-to-treat population,
respectively).
Results: Lixisenatide was superior to placebo in
reducing HbA1c (weighted, total mean difference
-0.57%; P = 0.002). More patients treated with
lixisenatide versus placebo achieved HbA1c
targets of B7% (49.1% vs. 28.4%, P = 0.003).
Lixisenatide was superior to placebo in lowering
2-h postprandial glucose (PPG) (weighted, total
mean difference -5.50 mmol/l, P = 0.0005).
More patients treated with lixisenatide versus
placebo achieved 2-h PPG targets of B7.8 mmol/l
(39.2% vs. 2.2%, P\0.0001). More patients
treated with lixisenatide versus placebo
achieved both an HbA1c target of B7% and a
2-h PPG target of B10 mmol/l (34.8% vs. 2.69%,
P\0.00001). The body weight of the lixisenatide
group tended to decrease. Lixisenatide was
generally well tolerated.
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INTRODUCTION
Globally, effective strategies for the clinical
management of type 2 diabetes mellitus
(T2DM) are receiving urgent attention as the
world’s T2DM population is nearly 400 million.
In Asia, the unprecedented rise in the
prevalence of T2DM is particularly alarming.
For instance, in China, the prevalence of T2DM
increased from 3.2% in 1996 to ca. 9.7% in
2013, with the Chinese T2DM population at
nearly 100 million, which represents
approximately a quarter of the world’s diabetic
population [1, 2].
Currently there is genuine concern about the
extent of poor glycemic control in a large
portion of the Asian T2DM population; for
instance, recent evidence has shown that
approximately two-thirds of patients in China
who are treated with oral antidiabetic drugs
(OADs) do not achieve the glycated hemoglobin
(HbA1c) targets of B6.5 or B7% [3–5].
Patients from East Asia with T2DM share
common pathophysiologic characteristics,
which are distinct from those of their
European counterparts. In East Asian countries
diabetes occurs at a much lower BMI than
elsewhere in the world [6], and the majority of
East Asians with prediabetes have impaired
glucose tolerance as opposed to impaired
fasting glucose [7]. Another feature
characterizing T2DM in Asian populations is
the tendency to develop young-onset diabetes.
Studies conducted in different East Asian
populations have found a mean age of
diagnosis of T2DM typically around 50 years
[8]. Impaired beta cell function plays an
important role in the pathogenesis of diabetes
in Asians, especially in those who are not
overweight or have a positive family history.
Importantly, HbA1c values seem to be higher
among Asians than Europeans, which is likely
related to genetic similarities [9]. In addition to
shared genetic and pathophysiological
characteristics, East Asians have similar dietary
habits. Therefore, a common treatment strategy
for this population is indicated.
Currently in East Asia, patients with T2DM
are commonly prescribed
metformin/sulfonylurea, and the initiation of
insulin therapy is often delayed [4, 5]. Because
inadequately controlled T2DM can give rise to
serious, irreversible medical complications,
there is thus an urgent need to identify
alternative treatment strategies that would
improve glycemic control in the East Asian
T2DM population.
Glucagon-like peptide-1 (GLP-1) receptor
agonists increase insulin release, suppress
glucagon secretion, and delay gastric
emptying, which has been shown to be an
effective strategy for improving glucose control
in T2DM [10]. Furthermore, GLP-1 agonists are
associated with a reduction in HbA1c levels, a
low incidence of hypoglycemia, and a reduction
in body weight [10]. GLP-1 receptor agonists are
generally well tolerated, and side effects are
mainly limited to mild gastrointestinal
disturbances in a relatively small proportion of
patients.
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Lixisenatide is a novel, once-daily prandial
GLP-1 receptor agonist for the treatment of
T2DM [11–16]. Its efficacy has been assessed
across the full spectrum of the natural history of
T2DM in a series of lixisenatide phase 3 studies
that were included in the GetGoal study
programme. The GetGoal clinical study
programme assessed glycemic control and
safety following lixisenatide treatment in
T2DM patients with uncontrolled glycemia
despite diet and exercise interventions, single
OADs, combinations of two or more OADs, or
basal insulin. In the GetGoal studies,
lixisenatide was found to be superior to
placebo in reducing HbA1c and postprandial
glucose (PPG) levels with a low incidence of
hypoglycemia. Accordingly, lixisenatide was
granted market authorization by the European
Medicines Agency in 2013.
In the GetGoal study programme, one study
enrolled only Asian patients who were
inadequately controlled by OADs, and an
additional four GetGoal randomized
controlled trials (RCTs) included Asian
patients in cohorts of mixed ethnicity. The
primary objective of this meta-analysis was to
amalgamate the safety and efficacy data of the
Asian T2DM patients enrolled in those five
RCTs, so as to broaden the database
concerning the safety and efficacy of
lixisenatide in Asian patients with T2DM who
do not achieve adequate glycemic control with
an established OAD regimen.
METHODS
Data Sources
To identify relevant clinical studies, we
performed a manual search on
ClinicalTrials.gov. Firstly, we searched for
lixisenatide phase 3 studies from the GetGoal
programme. The terms used in the search were
‘‘phase 3’’, ‘‘lixisenatide’’, and ‘‘GetGoal’’ and a
total of 13 studies were identified. Secondly, we
also searched on ClinicalTrials.gov and
pubmed.gov to make sure study primary
results had been published previously. Thirdly,
we further narrowed down to studies which had
enrolled Asian patients and evaluated
lixisenatide as an add-on treatment to OADs
and compared with placebo. The terms used in
this search were ‘‘Asian’’ and ‘‘OAD’’ and
‘‘placebo controlled’’. Five studies were
identified after this three-step search.
Analysis Design
The five randomized, placebo-controlled phase
3 studies of lixisenatide (GetGoal-M,
GetGoal-F1, GetGoal-S, GetGoal-P,
GetGoal-M-Asia) belonged to the GetGoal
study programme, which was a series of 11
multinational RCTs that investigated the
efficacy and safety profile of lixisenatide 20 lg
once daily across the spectrum of patients with
T2DM. All five of the RCTs included in the
present meta-analysis enrolled, amongst others,
Asian patients with T2DM who had inadequate
glycemic control (HbA1c C7%) despite an
established regimen of OADs. All patients
received either lixisenatide or placebo as an
adjunct to an established OAD regimen.
Patients self-administered the study drug
according to the regimens of the individual
trials. The designs of each of the RCTs have
been reported previously (see Table 1 for
information on the individual studies). Briefly,
GetGoal-M (NCT01169779) assessed the
efficacy and safety of lixisenatide as an adjunct
to metformin in patients with T2DM not
adequately controlled with metformin.
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Table 1 Individual study information
Study code
Short name



































20 lg, qd; or
OAD ? placebo qd




20 lg, qd (morning)
qd; or
OAD ? lixisenatide
20 lg, qd (evening)
qd; or
OAD ? placebo, qd
(morning) or
OAD ? placebo, qd
(evening)




20 lg, qd; or
OAD ? placebo qd
856 242 123 365
EFC11321
GetGoal-G-M-Asia
24 weeks OAD ? lixisenatide
20 lg, qd; or
OAD ? placebo qd
388 185 188 373
Overall 2887 503 338 841
ITT intent-to-treat
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GetGoal-F1 (NCT00713830) assessed the
efficacy and safety of four treatment schedules
with lixisenatide—a one-step or two-step dose
escalation, lixisenatide once daily for 12 weeks
as a one-step dose increase (10 lg for 2 weeks,
then 20 lg) or two-step dose increase (10 lg for
1 week, 15 lg for 1 week, then 20 lg)—as an
adjunct to metformin in patients with T2DM
not adequately controlled with metformin.
GetGoal-P (NCT00763815) assessed the
efficacy and safety of lixisenatide as an adjunct
to pioglitazone in patients with T2DM not
adequately controlled with pioglitazone.
GetGoal-S (NCT00713830) assessed the efficacy
and safety of lixisenatide as an adjunct to
sulfonylurea in patients with T2DM not
adequately controlled with sulfonylurea, and
GetGoal-M-Asia (NCT01169779) assessed the
efficacy and safety of lixisenatide in Asian
patients with T2DM inadequately controlled
by metformin (with or without sulfonylurea).
For the meta-analysis, the data on Asian
patients included in the five GetGoal studies
were extracted, amalgamated, and analyzed
according to the protocol of the meta-analysis.
The GetGoal programme was a series of phase 3,
randomized, placebo-controlled trials
conducted at centers across the globe. All
studies were sponsored by Sanofi.
Inclusion Criteria
Only GetGoal studies that included Asian adults
(men and women) with a confirmed diagnosis
of T2DM (as defined by the World Health
Organization, WHO) at least 1 year prior to
study entry were eligible for inclusion in the
meta-analysis. All patients had inadequate
glycemic control (HbA1c levels C7%) despite
an established regimen of OADs and were in the
intent-to-treat populations. In all of the
included studies, patients were randomly
assigned to either lixisenatide or placebo as an
adjunct to their usual OAD(s), and they
self-administered the study drug. The OADs
that were allowed in the studies included in this
meta-analysis were either metformin
(1.0–1.5 mg/day) ± sulfonylurea (at least half
of the maximum recommended dose as per
the package insert) or pioglitazone (at least
30 mg/day).
Endpoints
The primary endpoint of this meta-analysis
(and of the five GetGoal trials) was the mean
change in HbA1c from baseline to week 24.
Secondary endpoints included the number
of patients who achieved HbA1c target levels of
B7% at week 24; the mean change in 2-h PPG
values after a standardized meal test from
baseline to week 24; the number of patients
who achieved a PPG of B7.8 mmol/l at week
24; the number of patients who achieved an
HbA1c target of B7% as well as a 2-h PPG of 10
mmol/l at week 24; the mean change in fasting
plasma glucose (FPG); the mean change in
body weight from baseline to week 24; and the
number (%) of patients who experienced
treatment-emergent adverse events (TEAEs) or
serious TEAEs.
The data items extracted from each of the
selected studies are listed in Table 2, and the
main findings of the individual studies included
in the meta-analysis with regard to HbA1c
(percentage reduction), number of patients
who achieved HbA1c targets of B6.5% or B7%,
2-h PPG, and safety are listed in Tables S1–4 in
the supplementary material.
Statistical Methods
All meta-analyses were performed using
RevMan, version 5.3 (Cochrane Collaboration,
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Copenhagen). RevMan 5.3 was also used to
generate forest plots.
The following analysis populations were
identified: (1) the HbA1c population, which
included data from all randomized patients who
had at least one dose of the study drug
(lixisenatide or placebo) and one baseline and
one post-baseline HbA1c result; (2) the 2-h PPG
population, which included data from all
randomized patients who had at least one
dose of the investigational medicinal product
(IMP) and one baseline and one post-baseline
PPG result; (3) the FPG population, which
included data from all randomized patients
who had at least one dose of IMP and one
baseline and one post-baseline FPG result; (4)
the body weight analysis population, which
included all randomized patients who had at
least one dose of IMP and at least one baseline
and one post-baseline body weight
measurement; and (5) the safety population,
which included all randomized patients who
had at least one dose of study medication.
Descriptive statistics were used to measure
and describe the clinical characteristics and
patient demographic data, as well as to
measure and describe the efficacy and safety
outcomes. The number of patients and the
associated percentage of the total number of
patients with the relevant data reported were
determined for dichotomous variables. The
count, mean ± standard deviation (SD), and
median were reported for continuous
variables. Treatment arms within each group
were compared with one another, with P values
calculated using a Chi square (v2) test or analysis
of variance test where appropriate.
Standard meta-analytic techniques were
applied to assess the overall outcome measures
using a random-effects model with an inverse
variance method to determine weighted mean
differences with 95% confidence intervals (CIs)
Table 2 Data items extracted from selected studies
Demographics Age
Gender
Body weight and body mass index
HbA1c at study entry (baseline)
FPG at study entry (baseline)
Efﬁcacy
parameters
Change in HbA1c % from baseline (week 1) to end of treatment (week 24)
Number (%) of patients who achieved an HbA1c target of B7% at week 24
Change in 2-h PPG after a standardized meal administered at baseline and at the end of treatment
(week 24)
Number (%) of patients who achieved PPG B7.8 mmol/l at week 24
Change in FPG from baseline (week 1) to end of treatment (week 24)
Number (%) of patients who achieved FPG of B6.1 and B7.0 mmol/l
Change in body weight from baseline (week 1) to end of treatment (week 24)
Safety parameters Number (%) of patients with TEAEs and serious TEAEs
HbA1c glycated hemoglobin, FPG fasting plasma glucose, PPG postprandial glucose
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for continuous variables and Mantel–Haenszel
odds ratios for all dichotomous outcome data. A
P value of 0.05 was used to determine the level
of statistical significance.
Quantification of heterogeneity was
examined with I2 to measure the degree of
total variation across trials owing to
heterogeneity and establish the consistency of
evidence. I2 values greater than 50% indicate a
substantial level of heterogeneity; if
heterogeneity was observed, this was
accommodated using a random-effects model.
Compliance with Ethics Guidelines
All procedures in the trials included in this
current meta-analysis were in accordance with
the responsible committee on human
experimentation (institutional and national)
and with the Helsinki Declaration of 1964, as
revised in 2013. Informed consent was obtained
from all patients for being included in the
studies. This meta-analysis is based on
previously conducted studies, and does not
involve any new studies of human or animal
subjects performed by any of the authors.
RESULTS
In total, 883 Asian patients with T2DM were
available from the five GetGoal studies for
inclusion in the meta-analysis. All of the
patients had inadequate glycemic control
(HbA1c levels C7%) on an established regimen
of OADs (metformin ± sulfonylurea or
pioglitazone). Of the 883 patients, 536 were
assigned to lixisenatide and 347 to placebo as an
adjunct to the patients’ established OAD
regimen. The demographics of the analysis
populations for the meta-analysis are reported
in Table 3. The mean (SD) value of age, BMI,
weight, HbA1c, and FPG at baseline, and the
percentages of male patients were well balanced
between two treatment groups.
HbA1c %
Compared with placebo, lixisenatide 20 lg once
daily as an adjunct to an established OAD
regimen significantly reduced HbA1c from
baseline to week 24 in patients with
inadequate glycemic control (weighted, total
mean difference -0.57%; P = 0.002; Table 4).
The potential heterogeneity of the primary
endpoint was high (I2 = 79%), but this was
accommodated by the randomized-effects
model.
Number (%) of Patients Achieving HbA1c
Targets of £7%
Significantly more patients in the lixisenatide
versus the placebo treatment group achieved
the HbA1c targets of B7% (49.1% vs. 28.4%,
P = 0.003) (Table 5). The odds ratios (ORs) for
HbA1c B7% were 0.18 (0.06, 0.57,
random-effects model).
Two-hour PPG
Two-hour PPG was measured in three of the five
GetGoal studies only (GetGoal-M-Asia,
GetGoal-M, and GetGoal-S). Overall,
lixisenatide was superior to placebo in lowering
2-h PPG at the end of the 24-week treatment
period (weighted, total mean difference
-5.50 mmol/l, P = 0.0005). Table 6 shows the
change in 2-h PPG for lixisenatide versus placebo
for all the treatment groups. The potential
heterogeneity for the primary endpoint was
relatively high (I2 = 89%), but this was
accommodated using a random-effects model.
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Number (%) of Patients Achieving 2-h PPG
Targets of £7.8
Significantly more patients treated with
lixisenatide versus placebo achieved 2-h PPG
targets of B7.8 (39.2% vs. 2.2%, P\0.0001).
The OR for achieving a target of B7.8 mmol/l
was 0.06 (95% CI 0.01, 0.22), at the end of the
24-week treatment period (random-effects
model; see Table 7).
Number (%) of Patients Achieving
an HbA1c Target of £7% and a 2-h PPG
Target of £10 mmol/l
Significantly more patients treated with
lixisenatide versus placebo achieved both an
HbA1c target of B7% as well as a 2-h PPG
target of B10 mmol/l (34.8% vs. 2.69%,
respectively, P\0.00001). The OR for
achieving this composite endpoint was 0.07
(95% CI 0.03, 0.18) at the end of the 24-week
treatment period (random-effects model; see
Table 8).
FPG
Lixisenatide was superior to placebo in lowering
FPG (P\0.0001). The mean difference in FPG
between the lixisenatide and placebo groups at
the end of the 24-week treatment period was
-0.51 mmol/l (-0.76, -0.26; random-effects
model).
Change in Body Weight
Patients treated with lixisenatide generally had
a stable body weight with a trend towards a
decrease in body weight at the end of the
24-week treatment period [mean difference
between groups –0.29 kg (-0.60, 0.01), both
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Adverse Reactions
More patients in the lixisenatide versus placebo
group experienced one or more TEAEs [OR 0.60;
95% CI (0.45, 0.81), both fixed and
random-effects models].
In total, 12 of 347 (3.46%) patients in the
placebo treatment group and 17 of 536 (3.17%)
patients in the lixisenatide treatment group
experienced at least one serious TEAE (P = 0.49).
The risk ratios of serious adverse events did not
show any statistically significant differences
between lixisenatide and placebo group
[OR 1.31; 95% CI (0.61, 2.79), both fixed and
random-effects models].
Summary of Evidence
Overall, the evidence is sufficiently robust to
confirm that lixisenatide as an adjunct therapy
can improve glycemic control of HbA1c in
Asian T2DM patients who do not achieve
adequate glycemic control with OADs. Also,
lixisenatide was superior to placebo in lowering
2-h PPG at the end of the 24-week treatment
period. The improvements in glycemic control
and the decrease in 2-h PPG were statistically
significant and clinically meaningful.
DISCUSSION
This meta-analysis of more than 800 Asian
patients with T2DM shows that a once-daily
dose of 20 lg of lixisenatide can substantially
improve glycemic control in Asian patients who
do not achieve an HbA1c target of 7% with an
established regimen of OADs. Both HbA1c and
2-h PPG showed clinically meaningful
reductions, with the 2-h PPG reduction being
particularly large (-5.5 mmol/l) after the
24-week treatment course. Both HbA1c and
PPG are important components of glycemic
control, and the results of our meta-analysis
provide evidence that lixisenatide has clinical
Table 5 Forest plots for lixisenatide versus placebo in terms of percentage of patients with HbA1c values B7%





random, 95% CIEvents Total Events Total
GetGoal-F1 11 22 1 9 14.0 0.13 (0.01, 1.17)
Favors lixisenatide Favors placebo
GetGoal-M-Asia 107 185 84 188 30.3 0.59 (0.39, 0.89)
GetGoal-M 21 40 1 11 14.7 0.09 (0.01, 0.77)
GetGoal-S 100 242 9 123 27.9 0.11 (0.05, 0.23)
GetGoal-P 8 14 1 7 13.2 0.13 (0.01, 1.33)
Total (95% CI) 503 338 100 0.18 (0.06, 0.57)
Total events 247 96
Heterogeneity: s2 = 1.05; v2 = 19.31; df = 4 (P = 0.0007); I2 = 79%
Test for overall effect: Z = 2.94 (P = 0.003)
Random-effects model
CI conﬁdence interval, df degrees of freedom, HbA1c glycated hemoglobin, OR odds ratio
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application in Asian patients with T2DM who
are inadequately controlled with OADs.
HbA1c Reduction
Our meta-analysis found that, compared with
placebo, lixisenatide, on average, reduced
HbA1c by 0.57% after a 24-week treatment
period. This signifies a clinically meaningful
improvement in glycemic control in Asian
patients with T2DM who were inadequately
controlled with an established OAD regimen.
In the GetGoal-S study, which enrolled 859
patients of mixed ethnic origin (ca. 45% of
them were of Asian origin), the mean baseline
HbA1c level was 8.2–8.3%, and the magnitude
of the HbA1c reduction was 0.74%. This was
more than double that reported in the
GetGoal-M-Asia study, which enrolled 391
Asian patients (90% of them were Chinese) in
China, Malaysia, Thailand, and Hong Kong
[17, 18]. The mean baseline HbA1c of patients
in that study was relatively low (7.85–7.95%),
and the mean HbA1c reduction was
considerably lower than that in other similar
GetGoal studies that enrolled cohorts of mixed
ethnic origin. The mean reduction in HbA1c in
the present meta-analysis was greater than that
reported in the GetGoal-M-Asia study
(-0.36%). In our meta-analysis, the mean
baseline HbA1c for the lixisenatide and
placebo groups was 8.2% and 8.1%,
respectively. Previous studies with GLP-1
receptor agonists showed that higher baseline
HbA1c levels correlate with greater reductions
in HbA1c [19–23].
The results of our meta-analysis therefore
provide consolidated evidence for the value of
lixisenatide in achieving glycemic control in
Asian patients with T2DM who do not meet
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Antidiabetic drugs that target GLP-1 are
promising therapeutic options for Asian T2DM
patients and it is postulated that GLP-1 receptor
agonists increase glucose uptake, which, in
turn, improves peripheral glucose utilization
and measures of beta cell function [24, 25].
Two-hour PPG Reduction
The main antidiabetic effect of lixisenatide as a
prandial GLP-1 receptor agonist is to delay
gastric emptying, which, in turn, controls PPG
excursions [10]. Our meta-analysis reported a
large reduction in 2-h PPG (-5.5 mmol/l) after
the 24-week treatment with lixisenatide, which
was significantly better than that of the placebo
group (weighted, total mean difference -0.57%;
P = 0.0005). PPG control is a fundamental
component of glycemic control in Asian
T2DM because PPG excursions are thought to
be more pronounced in Asians than in
Westerners with T2DM [9, 26]. These
Table 7 Forest plots for lixisenatide versus placebo in terms of percentage of patients with PPG B7.8 mmol/l
Study Lixisenatide Placebo Weight
(%)
Odds ratio M-H, 95%
CI
Odds ratio M-H, random,
95% CIEvents Total Events Total
GetGoal-M-Asia 37 109 4 116 63.8 0.07 (0.02, 0.20)
Favors lixisenatide Favors placebo
GetGoal-M 7 19 0 4 16.8 0.19 (0.01, 3.94)
GetGoal-S 54 122 0 66 19.4 0.01 (0.00, 0.16)
Total (95% CI) 250 186 100 0.06 (0.01, 0.22)
Total events 98 4
Heterogeneity: s2 = 0.46; v2 = 2.70, df = 2 (P = 0.26); I2 = 26%
Test for overall effect: Z = 4.14 (P\0.0001)
Random-effects model
CI conﬁdence interval, df degrees of freedom, HbA1c glycated hemoglobin, OR odds ratio, PPG postprandial glucose
Table 8 Forest plot for lixisenatide versus placebo in terms of percentage of patients with both HbA1c B7% and PPG
B10 mmol/l




Odds ratio M-H, random,
95% CIEvents Total Events Total
GetGoal-M-Asia 39 109 5 116 81.7 0.08 (0.03, 0.21)
Favors lixisenatide Favors placebo
GetGoal-M 7 19 0 4 8.4 0.19 (0.01, 3.94)
GetGoal-S 41 122 0 66 9.9 0.01 (0.00, 0.24)
Total (95% CI) 250 186 100 0.07 (0.03, 0.18)
Total events 87 5
Heterogeneity: s2 = 0.00; v2 = 1.93; df = 2 (P = 0.38); I2 = 0%
Test for overall effect: Z = 5.80 (P\0.00001)
Random-effects model
CI conﬁdence interval, df degrees of freedom, HbA1c glycated hemoglobin, OR odds ratio, PPG postprandial glucose
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disparities are usually ascribed to differences in
eating/dietary habits, whereas physiological
variances, such as a faster beta cell
degeneration in Asian versus Western T2DM,
may also have a role [26]. Consequently, in
Asian T2DM, PPG is thought to be a more
important contributor to HbA1c than FPG, and
prandial GLP-1 receptor agonists are therefore a
valuable addition to the treatment arsenal for
Asian T2DM.
The reduction in PPG in our meta-analysis is
aligned with the results of other studies with
prandial GLP-1 agonists.
Body Weight
To date, GLP-1 receptor agonists have shown
some benefits in terms of stable body weight or
weight loss in T2DM patients. The effect of
T2DM treatment regimens on body weight is an
important consideration when selecting
treatments for glycemic control because
patients are often unwilling to commence,
comply with, or intensify treatments that
result in weight gain, in particular basal
insulin. Treatment intensification with GLP-1
receptor agonists may therefore present a useful
alternative to prandial insulin in patients
insufficiently controlled with OADs. The
results of this meta-analysis show that, at a
minimum, body weight was stable over the
24-week treatment period. There was a
tendency for weight loss at the end of the
study, which might intensify if treatment is
continued for a longer period. Nonetheless,
another similar study in the GetGoal study
programme (GetGoal-S) reported significantly
larger reductions in body weight for patients
treated with lixisenatide (mean reduction of
0.84 vs. –0.29 kg in this meta-analysis). In that
study, the mean baseline body weight of
patients was approximately 10 kg greater than
that of patients in the meta-analysis.
In general, Asian individuals develop T2DM
at a lower BMI than Westerners, and this could
explain the generally lower mean body weight
of the Asian cohort in our meta-analysis [23].
Nonetheless, in clinical practice, Asian
individuals with T2DM do achieve high body
weights and high BMIs, and these patients will
most likely experience a reduction in body
weight when treated with lixisenatide, similar
to that of cohorts with a higher mean body
weight in other GetGoal studies.
Safety
Although the incidence of TEAEs was higher in
the lixisenatide than in the placebo group, the
individual studies that were included in this
meta-analysis showed that lixisenatide is
generally well tolerated and the adverse events
mostly mild to moderate in intensity. GLP-1
receptor agonists have a generally safe profile,
and lixisenatide’s safety results are consistent
with that of other GLP-1 receptor agonists [6].
Limitations
Observation can alter the behavior of both
patients and physicians involved in clinical
trials, and this may influence outcome
measures, i.e., patients included in this
meta-analysis were generally compliant with
study protocols, and this may well not reflect
real-world circumstances. For instance, in one
of the GetGoal studies included in the
meta-analysis, a relatively large placebo effect
was observed in HbA1c, which is likely due to
better patient compliance to diet and lifestyle
changes because of more individualized care
that is associated with study enrollment [17].
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CONCLUSIONS
In the present meta-analysis, lixisenatide as an
adjunct therapy was superior to placebo in
lowering both HbA1c and 2-h PPG levels of
Asian patients with T2DM who were
inadequately controlled with an established
regimen of OADs. A 24-week treatment period
with lixisenatide resulted in a reduction of
0.57% in mean HbA1c and a large reduction
in 2-h PPG (-5.5 mmol/l). Patients in the
lixisenatide treatment group were significantly
more likely than those in the placebo group to
achieve HbA1c B7% and PPG targets.
Lixisenatide is generally well tolerated and the
adverse events mostly mild to moderate in
intensity. Taken together, lixisenatide as an
adjunct therapy has clinical application in
Asian patients with T2DM who are
inadequately controlled with OADs.
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